Dr. Michael Har-Noy of Immunovative Therapies, Ltd. says that checkpoint Blockade drugs block a molecule that cancer cells use to turn off immune cells that are armed and ready to kill. Yervoy blocks a molecule called CTLA-4 and Opdivo blocks a molecule called PD-1. When these molecules are blocked, immune cells are no longer blocked from killing the cancer. However,Dr. Michael Har-Noy notes that this mechanism works only if there is an existing immune response that is capable of killing the tumors.
Most cancer patients have not developed an effective immune response. For this reason, the response rates of checkpoint blockade drugs have been low or restricted to tumors that are highly immunogenic (such as melanoma). Dr. Michael Har-Noy has developed a novel technology that may serve as a platform to treat virtually all types of cancer and infectious diseases. This technology is different from previous immunotherapies that have failed clinically. Instead of being developed first in animals and then translated to humans, Dr. Michael Har-Noy's unique technology was reverse engineered from a human immune mechanism that has already been shown to be capable of killing chemotherapy-resistant metastatic cancers and that has been curative in many cases.
The immune effect that occurs after transplant of another person's immune cells (adult stem cells) into a cancer patient has been described as the most powerful anti-tumor mechanism ever discovered.Dr. Michael Har-Noy notes that this mechanism known as the “graft vs. tumor” effect or “GVT” is the only known mechanism for killing or debulking of chemotherapy-resistant metastatic disease. However, the clinical application of the GVT effect is severely limited due to an often lethal side-effect called “graft vs. host disease” or “GVHD” which is intimately associated with the GVT mechanism. The separation of the beneficial GVT effect from the detrimental GVHD effect has been described as the “holy grail” of transplantation research.
Dr. Michael Har-Noy has developed a drug named AlloStimTM which uses a patented “Mirror EffectTM” technology to create the curative effect of a transplant without the toxic GVHD.